Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nusinersen Safety and Efficacy in SMA (EMBRACE)
NCT02462759Phase 2Terminated
- Sponsor
- Biogen
- Start
- Aug 2015
- Primary completion
- Sep 2018
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of nusinersen in spinal muscular atrophy (SMA), sponsored by Biogen. Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 1080 days, Number of Participants With Change From Baseline in Clinical Laboratory Parameters up to 1080 days and 12 more. Started Aug 2015; status: terminated.
02
Drugs
nusinersen
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT02462759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02462759.